PT - JOURNAL ARTICLE AU - Montanucci, Ludovica AU - Brünger, Tobias AU - Bhattarai, Nisha AU - Boßelmann, Christian M AU - Kim, Sukhan AU - Allen, James P. AU - Zhang, Jing AU - Klöckner, Chiara AU - Fariselli, Piero AU - May, Patrick AU - Lemke, Johannes R. AU - Myers, Scott J. AU - Yuan, Hongjie AU - Traynelis, Stephen F. AU - Lal, Dennis TI - Distances from ligands as main predictive features for pathogenicity and functional effect of variants in NMDA receptors AID - 10.1101/2024.05.06.24306939 DP - 2024 Jan 01 TA - medRxiv PG - 2024.05.06.24306939 4099 - http://medrxiv.org/content/early/2024/05/08/2024.05.06.24306939.short 4100 - http://medrxiv.org/content/early/2024/05/08/2024.05.06.24306939.full AB - Genetic variants in genes GRIN1, GRIN2A, GRIN2B, and GRIN2D, which encode subunits of the N-methyl-D-aspartate receptor (NMDAR), have been associated with severe and heterogeneous neurologic diseases. Missense variants in these genes can result in gain or loss of the NMDAR function, requiring opposite therapeutic treatments. Computational methods that predict pathogenicity and molecular functional effects are therefore crucial for accurate diagnosis and therapeutic applications. We assembled missense variants: 201 from patients, 631 from general population, and 159 characterized by electrophysiological readouts showing whether they can enhance or reduce the receptor function. This includes new functional data from 47 variants reported here, for the first time. We found that pathogenic/benign variants and variants that increase/decrease the channel function were distributed unevenly on the protein structure, with spatial proximity to ligands bound to the agonist and antagonist binding sites being key predictive features. Leveraging distances from ligands, we developed two independent machine learning-based predictors for NMDAR missense variants: a pathogenicity predictor which outperforms currently available predictors (AUC=0.945, MCC=0.726), and the first binary predictor of molecular function (increase or decrease) (AUC=0.809, MCC=0.523). Using these, we reclassified variants of uncertain significance in the ClinVar database and refined a previous genome-informed epidemiological model to estimate the birth incidence of molecular mechanism-defined GRIN disorders. Our findings demonstrate that distance from ligands is an important feature in NMDARs that can enhance variant pathogenicity prediction and enable functional prediction. Further studies with larger numbers of phenotypically and functionally characterized variants will enhance the potential clinical utility of this method.Competing Interest StatementH.Y. and S.F.T. are co-inventors of Emory-owned intellectual property. S.F.T. is a member of the SAB for Sage Therapeutics, Eumentis Therapeutics, Neurocrine, the GRIN2B Foundation, the CureGRIN Foundation, and CombinedBrain. S.F.T. is a consultant for GRIN Therapeutics. H.Y. is the PI on a research grant from Sage Therapeutics and GRIN Therapeutics to Emory. S.F.T. is PI on a research grant from GRIN Therapeutics to Emory. S.F.T. is cofounder of NeurOp, Inc. and Agrithera. DL recieved funds from the Simons Foundation and GRIN Therapeutics.Funding StatementThis work was supported by NS111619 (ST), HD082373 (HY), and AG072142 (SJM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript